GIT Disorders: Comprehensive Biochemical Guide

1. PEPTIC ULCER DISEASE (PUD)

Normal Mucosal Defense Biochemistry

• Mucus gel barrier: Secreted by mucous neck glands; forms a physical barrier between lumen and epithelium
• HCO3- secretion: Gastric epithelial cells secrete bicarbonate, which is trapped in mucus. Any H+ that penetrates is neutralized before reaching cells; pepsin is also inactivated in this alkaline microenvironment
• Prostaglandin E2 (PGE2): Maintains the mucosal barrier and stimulates HCO3- secretion - this is WHY NSAIDs cause ulcers (they inhibit COX enzymes, blocking prostaglandin synthesis)
• Mucosal blood flow and growth factors (EGF, TGF-alpha) round out protection

Pathogenesis: Biochemical Imbalance

• Contains urease enzyme: converts urea → NH3 + CO2. NH3 alkalinizes the local microenvironment, allowing bacterial survival in the acid lumen and promoting colonization
• NH4+ (in equilibrium with NH3) is directly cytotoxic
• Releases CagA toxin (cytotoxin-associated gene A), which disrupts epithelial tight junctions and breaks down the protective mucus barrier
• In the antrum: inhibits somatostatin secretion from D cells → removes inhibition of G cells → excess gastrin → excess H+ secretion (indirect route to duodenal ulcer)
• Spreads to duodenum → inhibits duodenal HCO3- secretion, removing the buffer against excess acid
• Diagnostic test: 13C-urea breath test - patient drinks 13C-labeled urea; H. pylori urease converts it to 13CO2, which is absorbed, expired, and measured

• Inhibit COX-1 (constitutively expressed) → reduced PGE2 synthesis → loss of mucosal protection, reduced HCO3-, reduced mucosal blood flow
• Also have direct topical irritant effects (weak acids that accumulate in epithelial cells)

Types & Biochemical Differences

• Pancreatic islet cell adenoma secreting gastrin constitutively (not inhibited by luminal H+)
• Massive acid overload overwhelms duodenal HCO3- buffering
• Excess H+ inactivates pancreatic lipases → steatorrhea (fat maldigestion)
• Multiple ulcers from stomach through jejunum
• Treatment: H+ secretion inhibitors (omeprazole/PPIs - block H+/K+-ATPase; cimetidine - H2 receptor antagonist) + surgical tumor removal

• Pepsinogen (inactive precursor) secreted by chief cells and mucous cells
• Activated to pepsin when gastric pH drops (autocatalytic below pH 5)
• Pepsin is a protease - contributes to mucosal self-digestion once the barrier is breached
• Pepsinogen secretion stimulated by: vagal stimulation (cephalic phase) + local H+ reflexes

2. GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)

Biochemical Basis

• Lower esophageal sphincter (LES) incompetence allows gastric acid (H+, pH ~1-2) and pepsin to contact esophageal mucosa
• Esophageal epithelium lacks the mucous/HCO3- protective system of the stomach
• Repeated acid exposure:
  • Activates transient receptor potential (TRP) channels in sensory neurons → heartburn
  • Stimulates inflammatory cytokines (IL-8, IL-1β) → esophagitis
  • Chronic exposure → metaplasia: Barrett's esophagus (columnar intestinal-type epithelium replaces squamous epithelium) - a pre-malignant change driven by aberrant gene expression (CDX2 transcription factor) and DNA methylation changes
• Peptic injury occurs in esophagus from acid reflux, or from ectopic gastric mucosa in a Meckel diverticulum

3. INFLAMMATORY BOWEL DISEASE (IBD)

Shared Biochemical Pathogenesis

• NOD2 gene (Nucleotide Oligomerization Domain 2) - key susceptibility gene in Crohn disease
  • NOD2 encodes a pattern recognition receptor that binds intracellular bacterial peptidoglycans and activates NF-kB
  • Disease-associated NOD2 polymorphisms render it unable to effectively defend against intestinal bacteria → bacteria penetrate epithelium → trigger inflammatory cascades
• Autophagy-related genes (ATG16L1, IRGM): over 200 gene variants identified via GWAS; many encode components of the autophagosome pathway involved in handling intracellular bacteria
• Monozygotic twin concordance: ~50% in CD (strong genetic component) vs ~20% in UC (environmental factors more dominant)

• Trigger: microbial antigens presented to CD4+ Th cells → differentiation into Th1 and Th17 cells (driven by IL-12 and IL-23)
• Th1/Th17 cells activate macrophages, recruit neutrophils, release TNF-alpha, IFN-gamma, IL-17
• Crohn disease cytokine profile: IL-12, IL-23, IFN-gamma, TNF-alpha (Th1-dominated)
• Ulcerative colitis cytokine profile: Th2 shift with elevated IL-13 (causes epithelial damage)
• Regulatory T cell defects (especially IL-10-producing Tregs): rare mutations in IL-10 or IL-10 receptor → severe early-onset colitis
• Therapeutic targets: Anti-TNF antibodies (infliximab, adalimumab), anti-IL-12/23 antibodies (ustekinumab) - their efficacy confirms cytokine centrality

• Intestinal tight junction dysfunction in CD (cosegregates with NOD2 polymorphisms)
• Abnormal Paneth cell granules (contain antimicrobial peptides like defensins) → defective control of luminal microbiota composition
• Barrier dysfunction → antigen penetration → immune activation → more barrier damage (vicious cycle)

• IBD patients show reduced microbial diversity and shifts in microbial composition (dysbiosis)
• Reduced protective bacteria (e.g., Faecalibacterium prausnitzii which produces anti-inflammatory butyrate)
• Increased proinflammatory bacteria → amplified mucosal immune responses

Crohn Disease - Specific Features

• Transmural inflammation (all layers involved)
• Skip lesions - discontinuous disease distribution
• Granuloma formation (noncaseating) in ~35% - driven by macrophage activation
• Terminal ileum most commonly affected → impairs B12 absorption (requires ileal intrinsic factor receptors) → megaloblastic anemia
• Fat malabsorption (bile salt recycling disrupted in terminal ileal disease) → steatorrhea, fat-soluble vitamin (A, D, E, K) deficiencies
• Risk of oxalate kidney stones: unabsorbed fatty acids bind calcium → free oxalate is absorbed (hyperoxaluria)

Ulcerative Colitis - Specific Features

• Mucosal/submucosal inflammation only; limited to colon
• Continuous disease from rectum proximally
• Risk of toxic megacolon (massive colonic dilation from transmural inflammatory spread)
• Elevated IL-13 causes epithelial apoptosis, reduced mucus production, and barrier breakdown
• Long-standing UC → dysplasia → colorectal cancer risk

4. CELIAC DISEASE (Gluten-Sensitive Enteropathy)

Biochemical Pathogenesis

• Gluten (wheat protein) contains gliadin peptides that are resistant to full enzymatic digestion (proline-rich sequences resist intestinal proteases)
• Incompletely digested gliadin fragments cross the epithelial barrier (especially in genetically predisposed individuals with increased intestinal permeability)
• Tissue transglutaminase (tTG) in the lamina propria deaminates glutamine residues in gliadin peptides → modified peptides have high affinity for HLA-DQ2 and HLA-DQ8 molecules
• HLA-DQ2/DQ8 on antigen-presenting cells present deaminated gliadin to CD4+ Th1 cells → release of IFN-gamma, TNF-alpha → intestinal inflammation
• Autoantibodies: Anti-tTG IgA and anti-endomysial IgA (diagnostic markers); anti-gliadin antibodies also produced
• Anti-tTG antibodies cross-react with other tissues → extra-intestinal manifestations (dermatitis herpetiformis, cerebellar ataxia)
• Result: villous atrophy, crypt hyperplasia → massive reduction in absorptive surface area → global malabsorption

Consequences of Malabsorption (Biochemical)

5. CARBOHYDRATE MALABSORPTION DISORDERS

Lactase Deficiency (Lactose Intolerance)

• Lactase (beta-galactosidase) at brush border cleaves lactose → glucose + galactose
• Congenital or acquired loss of lactase activity
• Unabsorbed lactose enters colon → bacterial fermentation → H2, CO2, short-chain fatty acids → osmotic diarrhea, bloating, cramping
• Breath hydrogen test (elevated H2 after lactose load) is diagnostic

Sucrase-Isomaltase Deficiency

• Autosomal recessive; sucrase-isomaltase complex on brush border is deficient
• Cannot cleave sucrose (glucose + fructose) or isomaltose (alpha 1-6 bonds from starch digestion)
• Results in osmotic diarrhea on sucrose ingestion

Glucose-Galactose Malabsorption

• Mutations in SGLT1 (Na+/glucose cotransporter) in brush border
• Cannot absorb glucose or galactose
• Presents at birth with severe osmotic diarrhea when fed glucose- or lactose-containing formulas
• Fructose (absorbed via GLUT5) is tolerated

6. PANCREATIC DISORDERS

Acute Pancreatitis

• Normally, digestive enzymes are synthesized as inactive zymogens (trypsinogen, chymotrypsinogen, proelastase, prophospholipase A2, prolipase) and activated only in duodenal lumen by enterokinase (cleaves trypsinogen → trypsin), which then activates the rest
• In pancreatitis, zymogens are prematurely activated within acinar cells:
  • Trypsin activates other pro-enzymes → intracellular autodigestion cascade
  • Phospholipase A2 activated → damages cell membranes, produces lysolecithin (toxic)
  • Elastase activated → damages blood vessels → hemorrhage
  • Lipase activated → fat necrosis (saponification - fatty acids combine with calcium → calcium soaps → hypocalcemia is a complication)
• Activated trypsin also stimulates complement, kinin, and coagulation cascades → systemic inflammatory response

• Gallstones blocking common bile duct (reflux of bile into pancreatic duct activates phospholipase A2)
• Alcohol (causes ductal obstruction, directly stimulates premature zymogen activation)
• Hypercalcemia (activates trypsinogen)
• Mutations in PRSS1 (cationic trypsinogen) - hereditary pancreatitis; trypsin becomes resistant to autolysis

• Serum amylase and lipase elevated (leak from damaged acinar cells)
• Hypocalcemia (calcium sequestered in fat necrosis)
• Elevated CRP, WBC (systemic inflammation)

Chronic Pancreatitis

• Repeated acute attacks or chronic alcohol → progressive fibrosis, loss of acinar cells, loss of islet cells
• Exocrine insufficiency: Reduced lipase, protease, amylase → steatorrhea, protein maldigestion, B12 malabsorption (R-binder proteins not degraded)
• Endocrine insufficiency: Loss of beta cells → secondary diabetes mellitus (pancreatogenic diabetes)

Cystic Fibrosis and GIT

• CFTR (Cl- channel) dysfunction → thick, viscous secretions in pancreatic ducts → obstruction → autodigestion
• GI manifestations: meconium ileus (newborns), exocrine pancreatic insufficiency, distal intestinal obstruction syndrome

7. MALABSORPTION SYNDROMES

Pathophysiological Classification

Bile Salt Biochemistry in Malabsorption

• Bile salts are essential for micelle formation in the duodenum - solubilize dietary lipids and fat-soluble vitamins for absorption
• Primary bile acids (cholic acid, chenodeoxycholic acid) synthesized in liver from cholesterol (rate-limiting enzyme: cholesterol 7-alpha-hydroxylase)
• Conjugated with glycine or taurine → bile salts
• Reabsorbed in terminal ileum (enterohepatic circulation): 95% recycled, 5% lost in stool
• If terminal ileum is diseased/resected (Crohn disease): bile salt loss → reduced bile salt pool → fat malabsorption

Short Bowel Syndrome

• Massive small bowel resection → malabsorption of nearly everything
• Loss of brush border enzymes, transport proteins (SGLT1, GLUT2, CFTR, NHE3, PEPT1, etc.)
• Parenteral nutrition required until intestinal adaptation occurs (villous hypertrophy of remaining bowel driven by GLP-2)

8. DIARRHEAL DISORDERS

Osmotic Diarrhea

• Non-absorbable solutes in lumen → increased osmotic pressure → water drawn into lumen
• Examples: Lactase deficiency, Mg2+ laxatives, lactulose
• Stops with fasting
• High stool osmotic gap: Measured osmolality > 2x(Na + K)

Secretory Diarrhea

• Excess Cl- secretion or reduced Na+ absorption → obligatory water loss
• Cholera (Vibrio cholerae): CT-B subunit binds ganglioside GM1 on enterocytes; CT-A subunit ADP-ribosylates Gs-alpha → permanent activation of adenylyl cyclase → massive cAMP elevation → CFTR Cl- channels constitutively open → massive Cl- (and water) secretion → massive watery diarrhea (rice-water stools)
• E. coli LT toxin: Similar mechanism (ADP-ribosylates Gs)
• E. coli ST toxin: Activates guanylyl cyclase → elevated cGMP → activates CFTR
• VIPoma (Vasoactive Intestinal Peptide tumor): VIP activates adenylyl cyclase → watery diarrhea, hypokalemia, achlorhydria (WDHA syndrome)
• Continues despite fasting; normal osmotic gap

Invasive/Inflammatory Diarrhea

• Organisms (Salmonella, Shigella, C. difficile) invade or damage mucosa
• C. difficile: Toxin A (enterotoxin - disrupts tight junctions, induces apoptosis) + Toxin B (cytotoxin - inactivates Rho GTPases → cytoskeletal collapse → cell death) → pseudomembranous colitis

9. HEPATIC (LIVER) DISORDERS

Viral Hepatitis

• Hepatocyte injury biochemistry: Immune-mediated (CD8+ T cells kill infected hepatocytes) rather than direct viral cytopathicity (for HBV, HCV)
• Elevated ALT and AST (leak from damaged hepatocytes; ALT more liver-specific)
• Jaundice: impaired bilirubin conjugation and excretion

Cirrhosis

• End-stage of chronic liver injury: massive fibrosis, regenerative nodules
• Activated hepatic stellate cells (Ito cells) are the key fibrogenic cells - stimulated by TGF-beta1 to produce collagen type I and III → replacing functional parenchyma
• Portal hypertension (increased intrahepatic resistance due to fibrosis + active vasoconstriction by stellate cells)
• Biochemical consequences:
  • Reduced albumin synthesis → hypoalbuminemia → ascites, edema
  • Reduced clotting factor synthesis (II, V, VII, IX, X - all vitamin K-dependent factors, plus fibrinogen) → coagulopathy
  • Reduced cholesterol metabolism, altered lipoprotein profiles
  • Impaired drug metabolism (reduced CYP450 activity)
  • Impaired ammonia detoxification (urea cycle): ammonia accumulates → hepatic encephalopathy (ammonia disrupts astrocyte function; glutamine synthesis in astrocytes causes astrocyte swelling/cerebral edema)
  • Hyperaldosteronism (reduced aldosterone metabolism) → sodium and water retention

Non-Alcoholic Fatty Liver Disease (NAFLD/MASLD)

• Lipid accumulation in hepatocytes due to: insulin resistance → increased peripheral lipolysis (FFA flux to liver), increased de novo lipogenesis (elevated malonyl-CoA, SREBP-1c activation), impaired beta-oxidation and VLDL export
• Two-hit hypothesis: first hit (steatosis) + second hit (oxidative stress, mitochondrial dysfunction, inflammatory cytokines) → steatohepatitis → fibrosis

Wilson's Disease

• Autosomal recessive defect in ATP7B (copper-transporting ATPase in hepatocytes)
• Cannot incorporate copper into ceruloplasmin or excrete it into bile → copper accumulates in liver, brain, cornea (Kayser-Fleischer rings), kidneys
• Low serum ceruloplasmin, elevated urinary copper

Hemochromatosis

• HFE gene mutation (C282Y most common) → reduced hepcidin signaling → increased ferroportin activity on enterocytes → excess iron absorption
• Iron accumulates in liver (cirrhosis), pancreas (diabetes), heart (cardiomyopathy), skin (bronze pigmentation), gonads (hypogonadism) - "bronze diabetes"
• Elevated serum iron, transferrin saturation >45%, elevated ferritin

10. COLORECTAL CANCER (Biochemical Mechanisms)

1. APC/WNT pathway (chromosomal instability): APC mutation → accumulation of beta-catenin → activation of WNT target genes (MYC, cyclin D1) → cell proliferation. Adenoma-carcinoma sequence (APC → KRAS → SMAD4/TGF-beta loss → TP53 mutation)
2. Microsatellite instability pathway (MSI): Loss of DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2) → accumulation of mutations throughout genome → rapid carcinogenesis. Lynch syndrome is hereditary MMR deficiency.

11. ADDITIONAL NOTABLE GIT DISORDERS

Carcinoid Tumors (NETs)

• Arise from enterochromaffin cells; secrete serotonin (5-HT) from tryptophan via tryptophan hydroxylase + DOPA decarboxylase
• Carcinoid syndrome (when hepatic metastases present): flushing, diarrhea, bronchoconstriction from excess serotonin reaching systemic circulation
• Diagnosis: elevated urinary 5-HIAA (5-hydroxyindoleacetic acid, serotonin metabolite)
• Tryptophan diversion away from niacin synthesis → pellagra (niacin deficiency)

Whipple's Disease

• Infection with Tropheryma whipplei (gram-positive actinobactete)
• Infects macrophages in small bowel lamina propria; macrophages cannot digest bacteria (lysosomal defect)
• PAS-positive macrophages block lymphatics → lipid malabsorption, lymphedema

Hirschsprung's Disease

• Failure of neural crest cell migration → absence of ganglion cells (auerbach's myenteric and Meissner's submucosal plexuses) in distal colon
• Affected segment has tonic contraction (no inhibitory neurotransmission) → functional obstruction
• Loss of VIP and nitric oxide synthase (nNOS) neurons (inhibitory neurotransmitters) in affected segment

Ischemic Bowel Disease

• Bowel ischemia → reperfusion injury: xanthine oxidase generates reactive oxygen species (superoxide, H2O2, hydroxyl radical) on reperfusion → lipid peroxidation, DNA damage, cell death
• Mucosal injury releases bacterial endotoxin into portal circulation

Summary Biochemical Table

• Robbins & Kumar Basic Pathology - Chapters 13 (GI pathology)
• Costanzo Physiology 7th Edition - Chapter 8 (GI physiology/biochemistry), pp. 369-376
• Goodman & Gilman's Pharmacological Basis of Therapeutics - GI pharmacology, IBD chapter

Bile Disorders: Full Biochemical Guide

PART 1: NORMAL BILE BIOCHEMISTRY (Foundation)

1.1 Bile Acid Synthesis

• Rate-limiting enzyme: cholesterol 7alpha-hydroxylase (CYP7A1) - hydroxylates cholesterol at C-7
• CYP8B1 (sterol 12alpha-hydroxylase) determines the ratio of cholic acid (CA) to chenodeoxycholic acid (CDCA)
  • If CYP8B1 acts: produces cholic acid (CA) - trihydroxy bile acid (OH at C-3, C-7, C-12)
  • If CYP8B1 is bypassed: produces chenodeoxycholic acid (CDCA) - dihydroxy bile acid (OH at C-3, C-7)
• Quantitatively dominant in adult humans (90% of bile acid production)

• Cholesterol is first hydroxylated on the side chain by CYP27A1 (sterol 27-hydroxylase) to form 27-hydroxycholesterol
• Then acted on by CYP7B1 (oxysterol 7alpha-hydroxylase)
• Favors CDCA biosynthesis
• Dominant in neonates (CYP7A1 is poorly expressed at birth)
• Mutations in CYP7B1 cause severe neonatal cholestatic liver disease

1.2 Bile Acid Conjugation

• Enzyme: bile acid-CoA: amino acid N-acyltransferase (BAAT)
• First, bile acid is activated to a CoA thioester by bile acid-CoA ligase (BACL1/SLC27A5)
• Glycine conjugates predominate in humans (glycocholate, glycochenodeoxycholate)
• Taurine conjugates form a smaller fraction (taurocholate, taurochenodeoxycholate)
• Purpose of conjugation: Lowers pKa, keeps bile salts ionized and water-soluble at intestinal pH, increases amphiphilicity for micelle formation; also prevents passive reabsorption in the upper intestine

1.3 Secondary Bile Acid Formation (Gut Microbiota)

• 7alpha-dehydroxylation by colonic bacteria:
  • Cholic acid → Deoxycholic acid (DCA)
  • Chenodeoxycholic acid → Lithocholic acid (LCA) (most toxic; sulfated by liver for excretion)
• Bacterial bile salt hydrolases remove glycine/taurine from ~15% of bile acids in the small intestine (deconjugation)
• Ursodeoxycholic acid (UDCA) forms via epimerization of the C-7 hydroxyl of CDCA - the 7beta-isomer; it is hydrophilic and has cytoprotective/anti-apoptotic properties (used therapeutically)

1.4 Enterohepatic Circulation

1.5 Feedback Regulation of CYP7A1 (FXR-FGF19 Axis)

1. After a meal, bile acids are absorbed by terminal ileum enterocytes
2. Bile acids bind and activate FXR (Farnesoid X Receptor) - a nuclear receptor
3. FXR in ileal enterocytes induces synthesis of FGF19 (fibroblast growth factor 19)
4. FGF19 is secreted into portal circulation, reaches liver, and binds FGFR4/beta-klotho receptor complex on hepatocytes
5. FGFR4 signaling represses CYP7A1 transcription - inhibiting further bile acid synthesis
6. Additionally, FXR in hepatocytes induces SHP (small heterodimer partner) - an orphan nuclear receptor that inhibits HNF4alpha and LRH-1 (both are positive regulators of CYP7A1)
7. FXR also induces ZFP36L1 (RNA-binding protein) → promotes CYP7A1 mRNA degradation

PART 2: DISORDERS OF BILIRUBIN METABOLISM

Complete Bilirubin Pathway

Hemoglobin (heme)
    ↓ [Heme oxygenase - RES/macrophages, spleen]
Biliverdin (green)
    ↓ [Biliverdin reductase]
Unconjugated bilirubin (UCB) - lipid-soluble, tightly bound to albumin
    ↓ [Uptake into hepatocyte via OATP; bound to ligandin/Y-protein]
Unconjugated bilirubin (free, in hepatocyte)
    ↓ [UGT1A1 - UDP-glucuronosyltransferase in hepatocyte ER]
Conjugated bilirubin (bilirubin diglucuronide) - water-soluble
    ↓ [MRP2 - canalicular excretion into bile]
Bile → Intestine
    ↓ [Bacterial enzymes in colon]
Urobilinogen (some reabsorbed, appears in urine; most oxidized to urobilin → stercobilin → brown stool color)

2.1 Gilbert Syndrome

• Prevalence: 5-10% of population (most common inherited disorder of bilirubin metabolism)
• Defect: Mutation in the UGT1A1 gene promoter (TA repeat in the TATA box: (TA)7TAA instead of normal (TA)6TAA) → reduced transcription → ~30% of normal UGT1A1 activity
• Also: mildly reduced hepatic uptake of bilirubin
• Result: Mild unconjugated hyperbilirubinemia (usually <3 mg/dL), exacerbated by fasting, stress, illness, exercise
• Benign: No liver damage, no treatment needed
• Important pharmacological note: UGT1A1 also conjugates drugs (e.g., irinotecan, statins) - Gilbert patients have reduced drug glucuronidation → drug toxicity risk (e.g., irinotecan-induced diarrhea)

2.2 Crigler-Najjar Syndrome

• Kernicterus mechanism: UCB crosses blood-brain barrier (lipid-soluble when unbound from albumin) → deposits in basal ganglia → uncouples oxidative phosphorylation → neuronal death

2.3 Dubin-Johnson Syndrome

• Defect: Loss-of-function mutations in MRP2 (ABCC2) - the canalicular multispecific organic anion transporter
• Result: Conjugated bilirubin cannot be exported into bile canaliculus → refluxes back into blood → conjugated (direct) hyperbilirubinemia
• Mild jaundice; benign prognosis
• Characteristic: Black liver (lysosomal accumulation of dark pigment - a polymer of epinephrine metabolites that cannot be exported)
• Urine coproporphyrin pattern: total normal, but >80% is coproporphyrin I (normally majority is III)
• BSP (bromsulphthalein) dye test: biphasic curve with secondary rise at 90 min (reflux of conjugated BSP back into plasma)

2.4 Rotor Syndrome

• Defect: Mutations in OATP1B1 and OATP1B3 (sinusoidal uptake transporters) → impaired hepatic reuptake of conjugated bilirubin that has refluxed into plasma
• Result: Conjugated hyperbilirubinemia
• Liver appears normal (no black pigment - unlike Dubin-Johnson)
• Urine coproporphyrin: total elevated, normal ratio (I:III approximately equal)
• BSP: absent secondary rise (no reflux mechanism)

2.5 Neonatal Physiologic Jaundice

• Unconjugated hyperbilirubinemia in newborns (days 2-7)
• Mechanisms:
  1. Accelerated hemolysis (fetal Hb replacement with adult Hb)
  2. Immature UGT1A1 activity (also reduced UDP-glucuronate synthesis)
  3. Reduced ligandin (Y-protein) levels
  4. Increased enterohepatic circulation of bilirubin (intestinal beta-glucuronidase deconjugates bilirubin → reabsorbed)
• Treatment: Phototherapy (converts UCB to water-soluble photoisomers excreted in bile/urine without conjugation)

PART 3: GALLSTONE DISEASE (CHOLELITHIASIS)

3.1 Cholesterol Gallstones (75-80% of stones in Western countries)

• Cholesterol is water-insoluble; it is solubilized in bile by mixed micelles (bile acids + phospholipids/lecithin) and vesicles (phospholipid bilayer particles)
• The cholesterol saturation index (CSI) = (actual cholesterol) / (maximum solubilizable cholesterol)
• CSI >1 = supersaturated bile = lithogenic bile

• Excess cholesterol secretion (obesity, metabolic syndrome, estrogens)
  • Estrogens increase hepatic LDL receptor expression → increased cholesterol uptake → increased biliary cholesterol secretion; also increase HMG-CoA reductase activity
  • Oral contraceptives and pregnancy increase risk significantly
• Reduced bile acid pool (ileal disease/resection reduces enterohepatic cycling → less CDCA/CA → less micellar solubilization)
• Reduced phospholipid secretion (MDR3/ABCB4 mutations)

• Supersaturation alone is insufficient - crystal nucleation must occur within the mucin gel layer
• Pronucleating factors: mucin, certain immunoglobulins, pigment particles, calcium ions
• Antinucleating factors: Apolipoprotein A-I, Apolipoprotein A-II, certain glycoproteins
• UGT1A1 Gilbert variant is associated with gallstone disease - pigment particles (from incomplete bilirubin conjugation) act as nucleating foci
• Vesicle fusion → liquid crystals → solid cholesterol monohydrate crystals → crystal growth

• Impaired gallbladder emptying allows crystals to remain and grow into macroscopic stones
• CCK-mediated contraction is reduced in lithogenic states
• FGF19-TGR5 axis normally induces gallbladder filling/relaxation during fasting; impaired FGF19 signaling contributes
• High-risk states: pregnancy (progesterone reduces smooth muscle contraction), total parenteral nutrition (no enteral fat → no CCK release → gallbladder stasis), rapid weight loss, spinal cord injury

• ~25% genetic contribution
• ABCG5/ABCG8 variants → increased biliary cholesterol secretion
• CYP7A1 variants → reduced bile acid synthesis

• Pure cholesterol stones: pale yellow, radiolucent, ovoid, often single
• Mixed stones: more common, contain calcium carbonate/phosphates/bilirubin (some radiopaque)

3.2 Pigment Gallstones (20-25%)

• Sterile gallbladder bile
• Made of calcium bilirubinate polymer + calcium phosphate + calcium carbonate
• Mechanisms:
  • Chronic hemolysis (sickle cell disease, thalassemia, hereditary spherocytosis) → excess UCB production exceeds liver's conjugating capacity → elevated UCB in bile
  • Cirrhosis → reduced bile acid synthesis → reduced solubilization of bilirubin → precipitation
• Small, numerous, very hard, brittle
• Radiodense (calcium-containing)

• Found in infected bile ducts (intrahepatic or extrahepatic)
• Bacteria (E. coli, Bacteroides, Clostridium) produce beta-glucuronidase → deconjugates conjugated bilirubin in bile → forms insoluble calcium bilirubinate
• Soft, mushy, earthy-brown
• Associated with: bile duct strictures, choledochal cysts, Caroli disease, biliary parasites (Clonorchis sinensis, Ascaris)

3.3 Biliary Sludge

• Precursor to gallstones; contains lecithin-cholesterol liquid crystals, cholesterol monohydrate crystals, calcium bilirubinate, mucin gel
• Implies: (1) deranged mucin secretion/elimination balance; (2) nucleation of biliary solutes
• In 14% of patients, progresses to frank gallstones

3.4 Acute Cholecystitis

• Usually triggered by a stone obstructing the cystic duct
• Mechanical obstruction → bile stasis → increased intraluminal pressure → mucosal ischemia
• Biochemical cascade:
  • Concentrated bile (lithocholic acid, deoxycholic acid) causes mucosal damage (detergent action on cell membranes)
  • Phospholipase A2 in bile cleaves lecithin → lysolecithin (directly toxic to mucosa)
  • Prostaglandins (especially PGE2, PGI2) accumulate → inflammation, pain, fever
  • Secondary bacterial invasion (E. coli, Klebsiella, Enterococcus) in ~50% of cases

3.5 Choledocholithiasis and Ascending Cholangitis

• Stone in common bile duct → obstructive jaundice
• Charcot's triad: RUQ pain + fever + jaundice
• Cholestasis → alkaline phosphatase (ALP) and gamma-glutamyl transpeptidase (GGT) most prominently elevated (from cholestatic injury to cholangiocytes)
• Conjugated bilirubin elevated (secreted into bile but cannot pass obstruction → refluxes into blood via MRP3 on hepatocyte sinusoidal membrane)
• Bile acid accumulation in plasma → pruritus (bile acids deposit in skin, activating TGR5 and TRPV1 receptors on cutaneous sensory nerves)

PART 4: CHOLESTATIC LIVER DISEASES

4.1 Primary Biliary Cholangitis (PBC)

• Autoimmune destruction of small intrahepatic bile ducts (interlobular bile ducts, <100 microns)
• Key autoantigen: E2 subunit of the pyruvate dehydrogenase complex (PDC-E2) in the inner mitochondrial membrane
• Anti-mitochondrial antibodies (AMA) directed against PDC-E2: present in 95% of PBC patients with sensitivity and specificity >95%
• Why do cholangiocytes become targets? PDC-E2 is aberrantly expressed on the apical surface of biliary epithelial cells in PBC patients → becomes accessible to immune attack
• T cell-mediated injury: PDC-E2-specific CD4+ and CD8+ T cells are present in periductal stroma
• Histologic hallmark: "Florid duct lesion" - lymphocytic/granulomatous destruction of bile ducts in portal tracts
• Additional antibodies: ANA, anti-sp100, anti-gp210 (nuclear pore proteins)
• Elevated serum IgM (characteristic but unexplained)

• Elevated ALP, GGT (markers of biliary epithelial injury)
• Elevated conjugated bilirubin (late disease)
• Hypercholesterolemia: Bile acid feedback on CYP7A1 is lost → cholesterol accumulates; also impaired biliary cholesterol excretion
  • Xanthomas and xanthelasmas form (cholesterol deposits in skin/tendons)
  • Paradoxically, cardiovascular risk is NOT increased because the excess cholesterol is in HDL
• Fat malabsorption: Reduced bile acid pool → impaired micelle formation → steatorrhea
• Fat-soluble vitamin deficiencies:
  • Vitamin D deficiency → osteomalacia, osteoporosis
  • Vitamin K deficiency → coagulopathy (elevated PT/INR)
  • Vitamin A deficiency → night blindness
• Pruritus: Central mechanism involves excess bile acids and endogenous opioid accumulation; lysophosphatidic acid (LPA) generated by autotaxin (an enzyme upregulated in cholestasis) is the primary pruritogen
• Treatment: Ursodeoxycholic acid (UDCA) - hydrophilic bile acid that:
  • Replaces toxic hydrophobic bile acids in the pool
  • Has cytoprotective, anti-apoptotic, anti-inflammatory, choleretic effects
  • Activates FXR and TGR5 signaling
  • Obeticholic acid (OCA): Potent synthetic FXR agonist used in UDCA-refractory cases

4.2 Primary Sclerosing Cholangitis (PSC)

• Inflammation and obliterative fibrosis of extrahepatic AND large intrahepatic bile ducts
• 70% male; median age 30; strongly associated with IBD (especially ulcerative colitis) in ~70% of cases
• Classic ERCP/MRCP: "string and bead pattern" - multifocal strictures with adjacent dilations ("beading"); "pruning" of smaller ducts

• HLA associations: HLA-B8, DR3, DR4 → immune-mediated process
• Gut-liver axis hypothesis: In UC patients, T cells activated against gut antigens (possibly via molecular mimicry) migrate to liver and cross-react with bile duct antigens
• "Leaky gut" in IBD → bacterial products (LPS, secondary bile acids like DCA, LCA) reach liver via portal vein → trigger inflammatory injury to cholangiocytes
• Serological profile: pANCA positive (65%), AMA usually negative, IgG4 variable
• Biliary "bicarbonate umbrella" hypothesis: Normal cholangiocytes secrete HCO3- via AE2 anion exchanger, creating an alkaline layer that protects against toxic bile acids; in PSC, AE2 expression is reduced → cholangiocytes are exposed to toxic hydrophobic bile acids → apoptosis and injury

• Elevated ALP, GGT disproportionately
• Progressive bile duct loss → impaired bile flow → secondary biliary cirrhosis
• Portal hypertension → varices, ascites, hepatic encephalopathy
• High risk of cholangiocarcinoma (~15% lifetime risk) - DNA damage from chronic bile acid exposure activates oncogenic pathways (KRAS, TP53, IDH1/2 mutations)
• No medical therapy proven to alter disease course (UDCA reduces ALP but no survival benefit demonstrated); liver transplantation is definitive

4.3 Secondary Sclerosing Cholangitis

• Post-surgical strictures
• Choledocholithiasis
• Ischemic cholangiopathy (ICU patients with prolonged hypotension)
• AIDS cholangiopathy (CMV, Cryptosporidium)
• IgG4-associated cholangitis (responds to steroids, unlike PSC)

PART 5: PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

5.1 PFIC Type 1 - FIC1 Deficiency (Byler Disease)

• Gene: ATP8B1 (FIC1)
• Protein function: FIC1 is a P-type ATPase that acts as an aminophospholipid flippase, maintaining the asymmetric distribution of phospholipids in the canalicular membrane (phosphatidylserine on inner leaflet). This protects the membrane from the detergent action of bile salts.
• Without FIC1: Membrane integrity is lost → disrupted bile acid secretion → intrahepatic cholestasis
• Biochemistry: Low GGT (paradoxically - because phospholipid flipping defect impairs GGT activity), normal to low bile acids in bile, elevated bile acids in serum
• Presents in infancy/childhood with severe cholestasis, pruritus, growth failure
• Extra-hepatic manifestations: diarrhea (FIC1 is also expressed in intestine), hearing loss, pancreatitis

5.2 PFIC Type 2 - BSEP Deficiency

• Gene: ABCB11
• Protein function: Bile salt export pump (BSEP) - the primary ATP-dependent transporter secreting conjugated bile acids across the canalicular membrane into bile
• Without BSEP: Conjugated bile acids accumulate inside hepatocytes → direct hepatocellular toxicity → severe cholestasis → cirrhosis
• Biochemistry: Very low GGT, massively elevated serum bile acids (bile acid levels in serum can be 100x normal), elevated AST/ALT
• Most severe of the PFIC types; risk of hepatocellular carcinoma even in childhood
• BSEP is also inhibited by certain drugs (cyclosporine, rifampin, troglitazone) → drug-induced cholestasis

5.3 PFIC Type 3 - MDR3 Deficiency

• Gene: ABCB4
• Protein function: MDR3 is a phospholipid flippase (flips phosphatidylcholine/lecithin from inner to outer leaflet of canalicular membrane → lecithin is then secreted into bile)
• Lecithin in bile is critical: It forms mixed micelles with bile acids, preventing bile acids from acting as detergents on bile duct epithelium
• Without MDR3: Bile lacks lecithin → bile acids in unmicellized form directly damage cholangiocytes → biliary inflammation, sclerosing cholangitis-like picture
• Biochemistry: Elevated GGT (in contrast to PFIC 1 and 2!); bile is watery with very low phospholipid content; elevated serum ALP, GGT, conjugated bilirubin
• Adult presentation possible as "low-phospholipid-associated cholelithiasis (LPAC)" - recurrent cholesterol stones and biliary symptoms despite young age and absence of classical risk factors
• Treatment: UDCA (increases phospholipid secretion via alternative mechanisms)

PART 6: INHERITED DEFECTS IN BILE ACID SYNTHESIS

6.1 3beta-HSD Deficiency (HSD3B7)

• Most common inborn error of primary bile acid synthesis
• Cannot convert 3beta-hydroxy-Δ5 intermediates to the correct 3alpha-hydroxy configuration needed for CA and CDCA
• Atypical bile acids accumulate (3beta-hydroxy-Δ5 C27 bile acids) → toxic to hepatocytes → neonatal cholestasis
• Diagnosis: urine bile acid mass spectrometry shows characteristic atypical bile acids
• Treatment: oral CA/CDCA supplementation (replaces missing primary bile acids + suppresses CYP7A1 via FXR feedback)

6.2 Delta4-3-Oxosteroid 5beta-Reductase Deficiency (AKR1D1)

• Enzyme converts Δ4-3-oxo intermediates to 3-oxo-5beta configuration (required for correct sterol ring structure of bile acids)
• Accumulation of hepatotoxic Δ4-3-oxo bile acids
• Severe neonatal cholestasis and liver failure
• Treatment: primary bile acid replacement

6.3 CYP7A1 Deficiency

• Complete loss of the classical pathway
• Bile acid production reduced by ~90%
• Compensated by upregulation of the alternative pathway
• Adult presentation: hypercholesterolemia (cannot eliminate cholesterol as bile acids), gallstones
• Heterozygotes may have elevated LDL due to reduced CYP7A1 activity

6.4 Cerebrotendinous Xanthomatosis (CTX) - CYP27A1 Deficiency

• Gene: CYP27A1 (sterol 27-hydroxylase)
• Cannot hydroxylate the side chain of cholesterol → bile acid synthesis is defective (alternative pathway blocked)
• Accumulation of cholestanol (a reduced form of cholesterol) and bile alcohols in tissues
• Clinical features: Tendon xanthomas, cataracts, progressive neurological disease (cerebellar ataxia, dementia, spastic paraplegia), premature atherosclerosis
• Diagnosis: Elevated plasma cholestanol, elevated urinary bile alcohols
• Treatment: CDCA (suppresses CYP7A1 via FXR, reducing cholestanol synthesis) + statins

PART 7: DRUG-INDUCED CHOLESTASIS (BIOCHEMICAL MECHANISMS)

• Late-pregnancy estrogen and progesterone surges inhibit BSEP and MRP2
• Bile acids accumulate in maternal plasma → cross placenta → fetal distress, stillbirth risk
• Genetic predisposition: many ICP patients carry heterozygous mutations in ABCB11 or ABCB4
• Treatment: UDCA (restores BSEP function, reduces fetal bile acid exposure)

PART 8: BILE ACID MALABSORPTION (BAM)

• Loss of terminal ileum (Crohn disease, resection) → bile acids not reabsorbed → spill into colon
• In colon: bile acids stimulate Cl-/water secretion (activate TGR5 on colonocytes → cAMP → CFTR activation) → secretory diarrhea
• Also: bile acids induce 7alpha-dehydroxylation by colonic bacteria → excess deoxycholic acid (hydrophobic) → mucosal damage, increased colorectal cancer risk
• Bile acid pool depletion → reduced micellar solubilization → fat malabsorption (steatorrhea) when >100 cm ileum lost
• SeHCAT test (75Se-homotaurocholic acid retention) - diagnostic test for BAM
• Treatment: Bile acid sequestrants (cholestyramine, colesevelam) to bind excess bile acids in colon; UDCA for mild cases

PART 9: BILE DUCT TUMORS

Cholangiocarcinoma

• Malignancy of bile duct epithelium (cholangiocytes)
• Risk factors all involve chronic bile acid exposure and inflammation:
  • PSC, liver flukes (Clonorchis, Opisthorchis), hepatolithiasis, choledochal cysts
• Molecular biochemistry: Accumulation of lithocholic acid (secondary bile acid) promotes DNA damage (reactive oxygen species generation, NF-kB activation, AP-1 signaling); activates EGFR, VEGF pathways
• Key mutations: IDH1/2 (found in ~20% intrahepatic CC), FGFR2 fusions (~15% intrahepatic CC), KRAS, TP53, SMAD4
• Marker: CA 19-9 elevated (but not specific); CEA elevated
• IDH1/2 and FGFR2 are now therapeutic targets (ivosidenib for IDH1-mutant CC; pemigatinib, infigratinib for FGFR2-fusion CC)

Summary Reference Table: Key Biochemical Defects in Bile Disorders

• Sleisenger and Fordtran's Gastrointestinal and Liver Disease - Chapter 64 (Bile Acid Synthesis), Chapter 77 (Inborn Errors), Chapter 21 (Differential Diagnosis of Jaundice)
• Robbins, Cotran & Kumar Pathologic Basis of Disease - Chapter 18 (PBC, PSC)
• Robbins & Kumar Basic Pathology - Chapter 14 (Cholelithiasis)
• Harrison's Principles of Internal Medicine 22E - Gallstones chapter

Biochemistry of Bile Secretion

Overview

PART 1: Composition of Bile

1.1 Hepatic Bile (freshly secreted)

1.2 Gallbladder Bile (after concentration)

• Total solute concentration rises from 3-4 g/dL (hepatic bile) to 10-15 g/dL (gallbladder bile)
• Na+, Cl-, and HCO3- are greatly reduced (absorbed)
• Organic solutes (bile acids, phospholipids, bilirubin, cholesterol) are concentrated proportionally
• pH falls (from ~7.4 to ~6-7) due to bicarbonate reabsorption and proton secretion

PART 2: The Two Fundamental Mechanisms of Bile Formation

2.1 Bile Acid-Dependent Bile Flow (BADBF)

• Driven by the osmotic effects of bile acids concentrated in the canalicular lumen
• As bile acids are actively pumped into the bile canaliculus by BSEP (see Part 3), they create a high-osmolality zone
• Water follows osmotically through aquaporin channels (AQP8) on the canalicular membrane and via paracellular junctions (tight junctions between adjacent hepatocytes)
• Electrolytes (Na+, K+, Cl-) follow passively
• Each 1 µmol of taurocholate secretion produces ~8 µL of additional bile flow (from both BADBF and stimulation of ductular HCO3-/Cl- secretion)
• Bile flow correlates linearly with bile acid secretion rate

2.2 Bile Acid-Independent Bile Flow (BAIBF)

• Even with complete absence of bile acids, ~0.8-1.25 µL/min/g liver of bile flow persists
• Driven by secretion of two principal anions into the canaliculus:

• Secreted at 4-9 mM/min/g liver via MRP2/ABCC2 at the canalicular membrane
• GSH concentration in bile: 1-4 mM
• Once in bile, each GSH molecule is cleaved by gamma-glutamyl transpeptidase (GGT) on the canalicular surface: GSH → glutamate + cysteinyl-glycine
• The amino acid fragments act as osmotic drivers
• Direct correlation between GSH secretion and BAIBF

• Secreted into the canalicular lumen via the AE2 (anion exchanger 2 / SLC4A2) Cl-/HCO3- exchanger on the canalicular membrane
• HCO3- secretion creates an osmotic gradient for water entry
• Creates the "biliary bicarbonate umbrella" - an alkaline layer protecting the canalicular/ductal epithelium from the detergent/acid action of bile acids

PART 3: Hepatocyte Transport Biochemistry - Step by Step

Step 1 - Sinusoidal (Basolateral) Uptake

• Pumps 3 Na+ OUT and 2 K+ IN per cycle (using ATP)
• Creates: (1) inwardly directed Na+ chemical gradient; (2) inside-negative electrical potential of -35 to -40 mV
• These two driving forces are harnessed by all Na+-coupled cotransporters

• NTCP (Na+-taurocholate cotransporting polypeptide, SLC10A1): Primary transporter for conjugated bile acids. Cotransports 2 Na+ with 1 bile acid anion inward - uses both Na+ chemical gradient AND membrane potential. Achieves 40-fold concentration of bile acids inside hepatocyte vs. portal blood.
• OATP1B1 (SLCO1B1) and OATP1B3 (SLCO1B3): Na+-independent uptake - use the inside-negative membrane potential. Transport unconjugated bile acids, bilirubin-albumin complexes, drugs (statins, rifampin), and other organic anions. Critical pharmacological drug uptake transporters.

• Unconjugated bilirubin is bound to albumin in plasma
• Dissociates at the sinusoidal membrane; bilirubin enters hepatocyte either by facilitated diffusion or via OATPs
• Intracellularly, bound to ligandin (Y-protein / glutathione-S-transferase) - prevents it from diffusing back out

• Free fatty acids → bound to liver fatty acid-binding protein (L-FABP)
• Organic cations → via OCT (organic cation transporters)
• Drugs, hormones → via OATPs

Step 2 - Intracellular Transport

• Small lipophilic molecules (bile acids, fatty acids, bilirubin) are bound to intracellular binding proteins and carried across
• Bile acids are delivered to the Golgi apparatus, loaded into vesicles, and transported to the canalicular membrane

• Large proteins (secretory IgA, transferrin) bind specific sinusoidal receptors → undergo receptor-mediated endocytosis → vesicles traffic through the cytoplasm via microtubules → exocytosis at the canalicular membrane
• Hepatocytes maintain an extraordinarily high rate of membrane turnover (~5× entire plasma membrane area per hour), reflecting the intensity of vesicular trafficking

• Free bilirubin in hepatocyte cytoplasm → ER
• UGT1A1 (UDP-glucuronosyltransferase 1A1): transfers glucuronate from UDP-glucuronate to bilirubin
• Products: bilirubin monoglucuronide and bilirubin diglucuronide (the major form excreted)
• Conjugation renders bilirubin water-soluble for canalicular excretion

• Primary bile acids (CA, CDCA) are activated: bile acid-CoA ligase (BACL1/SLC27A5) forms bile acid-CoA thioester
• BAAT (bile acid-CoA:amino acid N-acyltransferase) conjugates the CoA thioester with glycine or taurine
• Glycine conjugates (glycocholate, glycochenodeoxycholate) predominate (ratio glycine:taurine = ~3:1 in humans)
• Purpose: Lowers pKa (from ~6 to ~2 for taurine; ~4 for glycine) → fully ionized at intestinal pH → stays in lumen, not passively absorbed → maintained in enterohepatic pool

Step 3 - Canalicular (Apical) Secretion

• AE2 (SLC4A2): Cl-/HCO3- anion exchanger → secretes HCO3- into bile (biliary bicarbonate umbrella)
• AQP8 (Aquaporin 8): Water channel on canalicular membrane; allows osmotically-driven water entry

• The canalicular membrane is exposed to highly concentrated bile acids (potential detergent injury)
• FIC1 is a flippase that maintains the asymmetric distribution of aminophospholipids (phosphatidylserine and phosphatidylethanolamine confined to the inner leaflet)
• This lipid asymmetry is essential for membrane stability and the function of all other ABC transporters
• Loss of FIC1 → ablation of ATP-dependent transporter function → cholestasis

PART 4: Ductular Bile Secretion - Cholangiocyte Biochemistry

The Secretin-cAMP-CFTR-AE2 Cascade (Choleresis)

• Duodenal S-cells release secretin in response to luminal acid (H+) from gastric emptying
• Secretin binds secretin receptor (SR) on the basolateral membrane of cholangiocytes (medium and large cholangiocytes only - small cholangiocytes lack SR)

• SR is coupled to Gs protein → activates adenylyl cyclase → increases intracellular cAMP
• cAMP activates Protein Kinase A (PKA)

• PKA phosphorylates CFTR (cystic fibrosis transmembrane regulator) on the apical membrane
• CFTR opens → Cl- efflux into the bile duct lumen
• A lumen-negative electrical potential is created

• Luminal Cl- accumulation + lumen-negative potential drives AE2 (Cl-/HCO3- exchanger): exchanges lumen Cl- back for intracellular HCO3- → net HCO3- secretion into bile
• This alkalinizes and dilutes bile

• The osmotic gradient created by Cl- and HCO3- drives water through:
  • AQP1 (aquaporin 1) on the apical (luminal) membrane
  • AQP4 (aquaporin 4) on the basolateral membrane

• Na+/K+/2Cl- cotransporter (NKCC1): Loads Cl- into cell for apical secretion
• Na+/H+ exchanger (NHE): Expels H+ to maintain intracellular pH
• Na+/HCO3- cotransporter (NBC): Imports HCO3- from blood
• K+ channels (SK2, IK1): K+ efflux hyperpolarizes the membrane → maintains driving force for continued Cl- secretion

• TMEM16A: Ca2+-activated Cl- channel; activated by intracellular Ca2+ increases (triggered by nucleotides, bile acids acting on apical P2Y receptors)
• LRRC8A: Volume-sensitive (osmo-sensitive) Cl- channel; activated during cell swelling
• G-protein regulated Cl- channel: Basolateral; role uncertain

• CFTR mutations → absent/dysfunctional CFTR in cholangiocytes → no Cl- efflux → no Cl-/HCO3- exchange → inspissated, dehydrated bile → bile duct obstruction → biliary cirrhosis in CF patients

Cholangiocyte Bile Acid Absorption (Cholehepatic Shunting)

• Reabsorbs some bile acids from bile duct lumen back into cholangiocytes
• Bile acids exit basolaterally via OSTalpha-OSTbeta heterodimer and t-ASBT (truncated ASBT)
• Re-enter hepatic arterial blood → return to hepatocytes → re-secreted into bile
• This "cholehepatic shunting" allows a portion of the bile acid pool to recirculate directly within the liver, bypassing the full enterohepatic circulation

PART 5: Regulation of Bile Secretion

5.1 Hormonal Regulation

5.2 Neural Regulation

• Parasympathetic (vagus nerve): ACh → M3 muscarinic receptors on hepatocytes and gallbladder → increases bile secretion and gallbladder contraction
• Sympathetic (adrenergic): Inhibits bile secretion; causes sphincter of Oddi contraction
• Vagal activity during the cephalic phase (sight/smell of food) pre-emptively increases bile flow before food reaches the duodenum

5.3 Nuclear Receptor Regulation (Transcriptional)

• Short-term rifampin activates PXR → induces CYP3A4 and UGT1A1 → bile acid hydroxylation and detoxification → anti-cholestatic effect (relieves pruritus)
• Long-term or high-dose rifampin inhibits NTCP and BSEP directly → reduces bile acid transport → worsens cholestasis

PART 6: Gallbladder Function in Bile Secretion

6.1 Storage and Concentration

• Sphincter of Oddi contracts
• Gallbladder relaxes (FGF19 promotes relaxation via TGR5)
• Bile secreted by liver is diverted into the gallbladder
• Gallbladder epithelium actively absorbs: Na+, Cl-, HCO3-, and water (following osmotic gradient)
  • Na+ absorbed via apical Na+/H+ exchanger and Na+/Cl- cotransporter
  • Cl- absorbed via Cl-/HCO3- exchanger and Cl- channels
  • Water follows via AQP1 and paracellular routes
• Result: 5-10x concentration of organic solutes (bile acids, bilirubin, cholesterol, phospholipids)

6.2 Gallbladder Mucin Secretion

• Gallbladder epithelium secretes mucin glycoproteins into bile
• Mucin lubricates the biliary tree
• Pathologically, mucin hypersecretion (stimulated by lithogenic bile) forms a gel that traps cholesterol crystals → promotes gallstone nucleation and growth

6.3 Gallbladder Emptying

1. Dietary fats and proteins in the duodenum → stimulate I-cells → release CCK
2. CCK binds CCK-A receptors on gallbladder smooth muscle → IP3/DAG pathway → intracellular Ca2+ rise → smooth muscle contraction
3. Simultaneously: CCK relaxes sphincter of Oddi (via VIP release from enteric neurons)
4. Vagal stimulation (parasympathetic) augments gallbladder contraction
5. Concentrated bile flows from gallbladder → cystic duct → common bile duct → sphincter of Oddi → duodenum

• Emptying fraction: ~75% per meal in normal subjects
• When gallbladder is absent (post-cholecystectomy): bile is stored in the proximal small intestine during fasting; pulsatile flow is maintained by the migrating motor complex; after a meal, small intestinal contractions deliver bile acids to the terminal ileum for reabsorption

PART 7: Bile Acid Function in the Intestinal Lumen

7.1 Micellar Solubilization

• Above their critical micellar concentration (CMC ~1.5-2 mM), bile acid molecules spontaneously aggregate into micelles
• Bile acid molecules are amphipathic: hydrophilic (hydroxyl groups) face outward; hydrophobic (sterol ring) faces inward
• Mixed micelles also incorporate lecithin (phosphatidylcholine): form larger, more effective solubilization units
• Mixed micelles solubilize: monoglycerides, fatty acids, fat-soluble vitamins (A, D, E, K), cholesterol, and other lipids
• Without micelles, lipid digestion products cannot cross the unstirred water layer to reach enterocyte brush border

7.2 Activation of Pancreatic Lipase

• Bile salts displace colipase from the oil-water interface of triglyceride droplets
• Colipase-pancreatic lipase complex then anchors to the surface → efficient triglyceride hydrolysis → monoglycerides + fatty acids

7.3 Electrolyte and Water Absorption

• Physiologic bile acid concentrations stimulate Na+ and water absorption in the small bowel
• In the colon at pathological concentrations (bile acid malabsorption): activate TGR5 → cAMP → Cl- secretion → secretory diarrhea (bile acid-induced diarrhea)

7.4 Bile Acid Signaling (Hormone-like Actions)

• FXR (nuclear receptor): In ileal enterocytes, liver, and other tissues; regulates bile acid metabolism, glucose homeostasis, lipid metabolism
• TGR5 (G-protein-coupled receptor): On cholangiocytes, gallbladder epithelium, enteroendocrine cells, brown adipose tissue, muscle; regulates gallbladder filling, gut motility, GLP-1 secretion (incretin effect), energy expenditure
• S1PR2 (sphingosine-1-phosphate receptor 2): On hepatocytes; activates NF-kB, regulates hepatic lipid metabolism

PART 8: Enterohepatic Circulation - The Complete Cycle

Liver (hepatocytes)
  ↓ BSEP secretes conjugated bile acids into canaliculi
  ↓ bile flows through canaliculi → ductules → bile ducts
  ↓ (cholangiocyte modification - HCO3-, water added)
  ↓ sphincter of Oddi relaxes (CCK)
Duodenum
  ↓ mixed micelle formation, fat digestion
  ↓ passive absorption along entire small intestine (unconjugated, some conjugated)
Terminal ileum
  ↓ ACTIVE uptake via ASBT (SLC10A2) - conjugated bile acids
  ↓ EXIT via OSTalpha/OSTbeta at basolateral membrane
Portal blood
  ↓ bile acids bound to albumin travel to liver
Hepatocyte (sinusoidal membrane)
  ↓ NTCP re-uptakes conjugated bile acids (Na+-coupled)
  ↓ OATPs uptake unconjugated bile acids
  ↓ Reconjugation with glycine/taurine
  ↓ Re-secretion via BSEP → cycle repeats

• Pool recycles 5-10 times/day
• 10-30 g bile acids reabsorbed/day from 2-4 g pool
• Fecal loss: 0.2-0.4 g/day (replaced by de novo synthesis from cholesterol)
• The maximum synthetic capacity is ~5 g/day; if intestinal losses exceed this (e.g., massive ileal resection), the pool cannot be replenished

Summary: Key Biochemical Cascade

CHOLESTEROL (hepatocyte)
    ↓ CYP7A1 (rate-limiting; inhibited by FXR-FGF19)
PRIMARY BILE ACIDS (Cholic acid, Chenodeoxycholic acid)
    ↓ BAAT (conjugation with glycine/taurine)
CONJUGATED PRIMARY BILE SALTS
    ↓ BSEP (ATP-dependent, canalicular)
BILE CANALICULUS (+ phospholipids via MDR3, cholesterol via ABCG5/G8,
                   bilirubin-glucuronide via MRP2, HCO3- via AE2,
                   GSH via MRP2)
    ↓ Cholangiocyte modification (Secretin→cAMP→CFTR→AE2: +HCO3-, +H2O)
BILE DUCT BILE
    ↓ Gallbladder concentration (NaCl/H2O absorbed, mucin added)
GALLBLADDER BILE
    ↓ CCK-stimulated contraction (meal)
DUODENUM: micelle formation → fat digestion → fat-soluble vitamin absorption
    ↓ Ileal ASBT active reabsorption (terminal ileum)
PORTAL BLOOD → HEPATOCYTE NTCP → Reconjugation → Re-secretion via BSEP
(Enterohepatic cycle: 5-10×/day)

• Yamada's Textbook of Gastroenterology, 7th Ed. - Chapter 19 (Mechanisms of Bile Formation), pp. 435-445
• Harrison's Principles of Internal Medicine 22E - Bile Secretion and Composition section
• Sabiston Textbook of Surgery - Bile Formation chapter, pp. 1574-1582
• Sleisenger and Fordtran's GI and Liver Disease - Chapter 64 (Transport proteins, enterohepatic circulation)